Fig. 2

ABCB1 and ABCG2 reversal agents significantly reverse gedatolisib resistance. a Dose-viability curves of SW620/ADR cells after treatment with different concentration of gedatolisib only or gedatolisib plus verapamil (5 μM) for 72 h. b Dose-viability curves of HEK293/ABCB1 cells after treatment with different concentration of gedatolisib only or gedatolisib plus verapamil (5 μM) for 72 h. c Dose-viability curves of LS180/MX cells after treatment with different concentration of gedatolisib only or gedatolisib plus Ko143 (5 μM) for 72 h. d Dose-viability curves of HEK291/ABCG2 cells after treatment with different concentration of gedatolisib only or gedatolisib plus Ko143 (5 μM) for 72 h. Data were shown with mean ± SD, which is representative for at least three independent experiments